JAK2 and acute myeloid leukemia: In acute myeloid leukemia (AML), YBX1 serves as a disease-sustaining mediator of jak2-mutated myeloproliferative neoplasms, enhancing the translational capacity of oncogenic transcripts (including MYC) by recruiting polysome chains, thereby driving the survival and proliferation of AML cells (18).